drugset / Trial / NCT04678336
CD123 Redirected T Cells for AML in Pediatric Subjects
NaSingle-groupOpen-labelTreatment
Summary
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).
Timeline
- Start
- 2021-04-02
- Primary completion
- 2025-05-09
- Completion
- 2025-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART123 cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CART123 cells | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | CART123 cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |